Amitiza lubiprostone: Phase IIb data

In a double-blind, dose-ranging Japanese Phase IIb study in 170 patients, 24 µg Amitiza twice daily met the primary endpoint of significantly increasing the mean SBM from baseline vs. placebo at week ...